( ase of actual'real-world' clinical out...)Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies,Health

ase of actual 'real-world' clinical outcomes. The sheer size of the sample as well as the consistency of its results across different hospital settings underscores the validity of the findings. The study controlled for six variables that could have confounded results, and derived data both for the total sample of nearly 25,000 babies as well as for a somewhat smaller group of more than 21,000 babies for whom complete and comparable data are available. For both groups, death rates were nearly 20% lower for babies treated with poractant alfa than for those treated with either beractant or calfactant."

RDS is a condition caused by a deficit in lung surfactant in infants who are born prematurely. Surfactant, a necessary and natural substance, is typically produced in the body about two months prior to birth and is required for proper respiratory function. By reducing the surface tension within the lungs, surfactant enables the lungs to inflate and normal breathing to begin at birth. However, when infants are born pre-term, surfactant may either be absent or be present only in insufficient quantities, preventing the lungs from inflating properly and possibly leading to the development of RDS. The administration of surfactants such as Curosurf(R) Intratracheal Suspension has been widely used to increase infant lung function and decrease the morbidity and mortality associated with RDS.

Rangasamy Ramanathan, MD, Professor of Pediatrics, Keck School of Medicine of the University of Southern California, Associate Division Chief, USC Division of Neonatal Medicine, and Section Head, Division of Neonatology and Neonatal Intensive Care Unit, LAC and USC Women's & Children's Hospital, noted: "I find it intriguing that this very large retrospective study confirms the direction of our own research a few years ago. In a randomized, multi- center trial that was published in the American Journal of Perinatology in 2004, we found a significantly higher survival rate am
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
2. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
3. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
4. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
7. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
8. DVT Awareness Survey Findings: Heart and Respiratory Patients
9. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
10. New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death
11. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery